Search Results - "LONG, Michael E"

Refine Results
  1. 1

    Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non–Small-Cell Lung Cancer by THIENELT, Christiane D, BUNN, Paul A, HANNA, Nasser, ROSENBERG, Arthur, NEEDLE, Michael N, LONG, Michael E, GUSTAFSON, Daniel L, KELLY, Karen

    Published in Journal of clinical oncology (01-12-2005)
    “…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have demonstrated antitumor activity in patients with non-small-cell lung cancer (NSCLC)…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Pharmacokinetics of combined doxorubicin and paclitaxel in mice by Gustafson, Daniel L., Merz, Andrea L., Long, Michael E.

    Published in Cancer letters (08-04-2005)
    “…Doxorubicin (DOX) has excellent antitumor activity when combined with paclitaxel (PTX) and this combination is used as first-line treatment for metastatic…”
    Get full text
    Journal Article
  4. 4

    Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo by Gustafson, Daniel L, Siegel, David, Rastatter, Jeffrey C, Merz, Andrea L, Parpal, Jacqueline C, Kepa, Jadwiga K, Ross, David, Long, Michael E

    “…The bioreductive activation of the antitumor quinone mitomycin C (MMC) by NAD(P)H: quinone oxidoreductase 1 (NQO1) is complicated by the ability of MMC to also…”
    Get more information
    Journal Article
  5. 5

    Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model by Gustafson, Daniel L, Rastatter, Jeffrey C, Colombo, Tina, Long, Michael E

    Published in Journal of pharmaceutical sciences (01-06-2002)
    “…The studies described herein were designed to determine whether doxorubicin (DOX) pharmacokinetics (PKs) could be described by a physiologically based PK model…”
    Get more information
    Journal Article
  6. 6

    Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues by Zirrolli, Joseph A., Bradshaw, Erica L., Long, Michael E., Gustafson, Daniel L.

    “…ZD6474 ( N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy] quinazolin-4-amine) is a tyrosine kinase inhibitor with anti-angiogenic and…”
    Get full text
    Journal Article
  7. 7

    Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay by GUSTAFSON, Daniel L, LONG, Michael E, ZIRROLLI, Joseph A, DUNCAN, Mark W, HOLDEN, Scott N, PIERSON, A. Scott, ECKHARDT, S. Gail

    Published in Cancer chemotherapy and pharmacology (01-08-2003)
    “…Docetaxel is a semisynthetic taxane derived from the needles of the European yew ( Taxus baccata) and it is an important chemotherapeutic agent in the…”
    Get full text
    Journal Article
  8. 8

    P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing by GUSTAFSON, Daniel L, LONG, Michael E, BRADSHAW, Erica L, MERZ, Andrea L, KERZIC, Patrick J

    Published in Cancer chemotherapy and pharmacology (01-09-2005)
    “…Paclitaxel (Taxol) is an effective agent against a broad range of human cancers. Studies on the metabolism and disposition of paclitaxel have shown that it is…”
    Get full text
    Journal Article
  9. 9

    Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma by Selting, K.A, Ogilvie, G.K, Gustafson, D.L, Long, M.E, Lana, S.E, Walton, J.A, Hansen, R.A, Turner, A.S, Laible, I, Fettman, M.J

    “…To determine the effect of dietary n-3 fatty acids on the pharmacokinetics of doxorubicin in dogs with lymphoma. 23 dogs with lymphoma in stages IIIa, IVa, and…”
    Get full text
    Journal Article
  10. 10

    Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: implications for pharmacokinetics in multiple dosing regimens by Gustafson, Daniel L, Long, Michael E

    Published in Chemico-biological interactions (25-10-2001)
    “…The purpose of the studies presented here is to determine if alterations in doxorubicin (DOX) pharmacokinetics that seem to occur following multiple-dosing are…”
    Get full text
    Journal Article
  11. 11

    Stochastic Simulation of Hepatic Preneoplastic Foci Development for Four Chlorobenzene Congeners in a Medium-Term Bioassay by Ou, Ying C., Conolly, Rory B., Thomas, Russell S., Gustafson, Daniel L., Long, Michael E., Dobrev, Ivan D., Chubb, Laura S., Xu, Yihua, Lapidot, Smadar A., Andersen, Melvin E., Yang, Raymond S. H.

    Published in Toxicological sciences (01-06-2003)
    “…A combination of experimental and simulation approaches was used to analyze clonal growth of glutathione-S-transferase π (GST-P) enzyme-altered foci during…”
    Get full text
    Journal Article
  12. 12

    Evidence for hepatocarcinogenic activity of pentachlorobenzene with intralobular variation in foci incidence by THOMAS, R. S, GUSTAFSON, D. L, POTT, W. A, LONG, M. E, BENJAMIN, S. A, YANG, R. S. H

    Published in Carcinogenesis (New York) (01-10-1998)
    “…Pentachlorobenzene (PeCB) is an important environmental contaminant derived primarily from the by-product contamination of the popular fungicides…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    When Sherman Marched North from the Sea: Resistance on the Confederate Home Front by Long, Michael E.

    Published in The Journal of African American History (01-04-2004)
    “…Long reviews When Sherman Marched North from the sea: Resistance on the Confederate Home Front by Jacqueline Glass Campbell…”
    Get full text
    Book Review
  19. 19

    A Single Grand Victory: The First Campaign and Battle of Manassas by Long, Michael E.

    “…Long reviews "A Single Grand Victory: The First Campaign and Battle of Manassas" by Ethan S. Rafuse…”
    Get full text
    Book Review
  20. 20